keyword
https://read.qxmd.com/read/37605331/use-of-the-opioid-receptor-antagonist-naltrexone-in-the-treatment-of-non-suicidal-self-injury
#21
JOURNAL ARTICLE
Hanna Karakuła-Juchnowicz, Agnieszka Banaszek, Dariusz Juchnowicz
AIM: The aim of the study was to review the existing research, conducted on animal and human models, regarding the possibility of using low doses of naltrexone (LDN) in treatment of non-suicidal self-injury (NSSI). METHOD: The available Polish - and English-language literature on NSSI was reviewed. Relevant studies were identified through an electronic search of PubMed/MEDLINE and Google Scholar databases using the following keywords: non-suicidal self-injury, NSSI, naltrexone, LDN, self-injury, self-harm, and time descriptors 1982-2022...
June 15, 2023: Psychiatria Polska
https://read.qxmd.com/read/37505425/the-utilization-of-low-dose-naltrexone-for-chronic-pain
#22
JOURNAL ARTICLE
Salomon Poliwoda, Bryant Noss, Gia Thinh D Truong, Zachary A Creech, Sarang S Koushik, Ivan Urits, Omar Viswanath
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone has a benefit in preventing relapse by reducing opioid cravings and reducing symptoms of opioid withdrawal. The benefits of this drug were not only shown with opioid abuse. In 1984 this drug was also approved for alcohol abuse. Naltrexone has been proven to decrease alcohol relapse by decreasing the craving...
August 2023: CNS Drugs
https://read.qxmd.com/read/37490616/ocular-surface-itch-and-pain-key-differences-and-similarities-between-the-two-sensations
#23
JOURNAL ARTICLE
Shyamal Raolji, Preet Kumar, Anat Galor
PURPOSE OF REVIEW: To review the pathophysiology and treatment of ocular itch and pain, encompassing nociceptive and neuropathic categories. RECENT FINDINGS: Ocular itch and pain are sensations that arise from activation of ocular surface polymodal nerves. Nociceptive itch, commonly comorbid with ocular pain complaints, is mainly driven by a histamine-mediated type 1 hypersensitivity reaction. Beyond topical therapy, novel drug delivery systems are being explored to improve ocular residence time of nonsteroidal anti-inflammatory drugs (NSAIDs) and antihistamines...
July 25, 2023: Current Opinion in Allergy and Clinical Immunology
https://read.qxmd.com/read/37456515/low-dose-naltrexone-as-treatment-for-epidermolysis-bullosa-pruriginosa-associated-refractory-pruritus
#24
Lauren C LaMonica, Margaret Lang-Houser, Scott C Bresler, Julie E Mervak
No abstract text is available yet for this article.
August 2023: JAAD Case Reports
https://read.qxmd.com/read/37371715/opiate-antagonists-for-chronic-pain-a-review-on-the-benefits-of-low-dose-naltrexone-in-arthritis-versus-non-arthritic-diseases
#25
REVIEW
Praneet Dara, Zeba Farooqui, Fackson Mwale, Chungyoul Choe, Andre J van Wijnen, Hee-Jeong Im
Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients...
June 2, 2023: Biomedicines
https://read.qxmd.com/read/37337611/low-dose-naltrexone-ldn-for-chronic-pain-at-a-single-institution-a-case-series
#26
JOURNAL ARTICLE
Anne Marie McKenzie-Brown, David W Boorman, Kristen R Ibanez, Ezihe Agwu, Vinita Singh
PURPOSE: Low-dose naltrexone (LDN) has increased in popularity as a non-opioid medication that may decrease chronic pain symptoms. LDN is most commonly used to treat fibromyalgia, complex regional pain syndrome (CRPS), and painful diabetic neuropathy. Other studies suggest that LDN provides general symptom reduction in inflammatory conditions such as Crohn's disease and multiple sclerosis. We reviewed our experience with patients to whom we have prescribed LDN to see what types of painful conditions were most responsive to LDN in our patient population...
2023: Journal of Pain Research
https://read.qxmd.com/read/37302106/low-dose-naltrexone-s-utility-for-non-cancer-centralized-pain-conditions-a-scoping-review
#27
REVIEW
Adam Rupp, Erin Young, Andrea L Chadwick
BACKGROUND: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activation within the central nervous system. One of the most likely contributors to centralized pain is changes in microglial cell processing. Therefore, it has been postulated that LDN can be used to manage patients with pain resulting from central sensitization due to this relationship. This scoping review aims to synthesize the relevant study data for LDN as a novel treatment strategy for various centralized pain conditions...
November 2, 2023: Pain Medicine
https://read.qxmd.com/read/37223594/low-dose-naltrexone-in-rheumatological-diseases
#28
REVIEW
Jozélio Freire de Carvalho, Thelma Skare
BACKGROUND: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders. AIM: To review the use of LDN in rheumatic diseases: systemic sclerosis (SSc), dermatomyositis (DM), Sjögren's syndrome (SS), rheumatoid arthritis (RA), and fibromyalgia (FM). METHODS: PubMed and Embase databases were searched for articles on LDN and rheumatic diseases between 1966 and August 2022...
March 2023: Mediterranean journal of rheumatology
https://read.qxmd.com/read/37206027/a-systematic-literature-review-on-the-clinical-efficacy-of-low-dose-naltrexone-and-its-effect-on-putative-pathophysiological-mechanisms-among-patients-diagnosed-with-fibromyalgia
#29
REVIEW
Sarah Partridge, Lisa Quadt, Monica Bolton, Jessica Eccles, Charlie Thompson, Alessandro Colasanti, Stephen Bremner, Christopher Iain Jones, Karin Due Bruun, Harm Van Marwijk
BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia prescribed LDN have reduced pain scores and greater quality of life compared with those allocated to placebo in randomized controlled trials. Secondly to determine if changes in inflammatory markers and brain structure and function are observed among patients with fibromyalgia taking LDN...
May 2023: Heliyon
https://read.qxmd.com/read/37189705/efficacy-of-low-dose-naltrexone-and-predictors-of-treatment-success-or-discontinuation-in-fibromyalgia-and-other-chronic-pain-conditions-a-fourteen-year-enterprise-wide-retrospective-analysis
#30
JOURNAL ARTICLE
C Noelle Driver, Ryan S D'Souza
Current pharmacologic treatments may provide limited analgesia in fibromyalgia and other chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic option that has been minimally explored. This study aims to describe current real-world prescribing practices of LDN, to investigate if patients have a perceived benefit of LDN in treating pain symptoms and to identify predictors associated with a perceived benefit or discontinuation of LDN. We evaluated all outpatient prescriptions for LDN prescribed for any pain indication in the Mayo Clinic Enterprise from 1 January 2009 to 10 September 2022...
April 3, 2023: Biomedicines
https://read.qxmd.com/read/37166576/acute-low-dose-naltrexone-increases-%C3%AE-endorphin-and-promotes-neuronal-recovery-following-hypoxia-ischemic-stroke-in-type-2-diabetic-mice
#31
JOURNAL ARTICLE
Rashmi Kumari, Zainab Y Kareem, Patricia J McLaughlin
Diabetic patients experience significant mortality and poor recovery following ischemic stroke. Our clinical and basic science studies demonstrate an overall immune suppression in the periphery of diabetic stroke patients, as well as within the central nervous system (CNS) of type-2 diabetic mice following hypoxia-ischemia (HI). Low doses of naltrexone (LDN) improved clinical outcomes in many autoimmune diseases by acting on opioid receptors to release β-endorphin which in turn balances inflammatory cytokines and modulates the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) pathway...
May 11, 2023: Neurochemical Research
https://read.qxmd.com/read/37151190/immobilization-of-raccoons-procyon-lotor-with-nalbuphine-medetomidine-and-azaperone
#32
JOURNAL ARTICLE
Emily E Doub, Alec T Thompson, Avery L Korns, Christopher A Cleveland, Michael J Yabsley, Mark G Ruder
Chemical immobilization is widely used by wildlife and veterinary professionals for the safe handling of animals. A combination of nalbuphine (40 mg/mL), azaperone (10 mg/mL), and medetomidine (10 mg/mL), known as NAM, is a low-volume combination with field immobilization practicality and fewer regulations restricting its use in the US than some other drug combinations. We evaluated the safety and effectiveness of NAM as an immobilizing agent for raccoons (Procyon lotor). From May 2021 to February 2022, 16 adult raccoons were captured in cage traps and immobilized with 0...
May 8, 2023: Journal of Wildlife Diseases
https://read.qxmd.com/read/37151015/long-term-effects-of-low-dose-naltrexone-on-immunomodulatory-properties-of-human-adipose-derived-mesenchymal-stem-cells
#33
JOURNAL ARTICLE
Romina Kazemi, Mobin Mohammadi, Samira Salimiyan, Sara Aliakbari, Moslem Ahmadi, Rahmani Mohammad Reza
BACKGROUND: Low-dose naltrexone (LDN) is involved in the treatment of inflammatory and immune system diseases and can affect immune cells. Mesenchymal stem cells (MSCs) are known for their immunomodulatory effects and the potential for the treatment of certain types of autoimmune diseases. OBJECTIVE: To investigate the long-term effects of LDN on human adipose-derived mesenchymal stem cells (ASCs) to see how their immunomodulatory properties are affected and also how LDN-treated ASCs interact with other immune cells present in peripheral blood mononuclear cells (PBMCs)...
May 31, 2023: Iranian Journal of Immunology: IJI
https://read.qxmd.com/read/37139343/climbing-behavior-by-mice-as-an-endpoint-for-preclinical-assessment-of-drug-effects-in-the-absence-and-presence-of-pain
#34
JOURNAL ARTICLE
Edna J Santos, Arianna N Giddings, Farah A Kandil, S Stevens Negus
This study evaluated climbing in mice as a tool to assess the expression and treatment of pain-related behavioral depression in male and female ICR mice. Mice were videotaped during 10-min sessions in a vertical plexiglass cylinder with wire mesh walls, and "Time Climbing" was scored by observers blind to treatments. Initial validation studies demonstrated that baseline climbing was stable across repeated days of testing and depressed by intraperitoneal injection of dilute lactic acid (IP acid) as an acute pain stimulus...
2023: Front Pain Res (Lausanne)
https://read.qxmd.com/read/37045708/pilot-study-of-low-dose-naltrexone-for-the-treatment-of-chronic-pain-due-to-arthritis-a-randomized-double-blind-placebo-controlled-crossover-clinical-trial
#35
RANDOMIZED CONTROLLED TRIAL
Britte Beaudette-Zlatanova, Robert A Lew, John D Otis, Westyn Branch-Elliman, Eugene Bacorro, Maureen Dubreuil, Caroline Eyvazzadeh, Maneet Kaur, Antonio A Lazzari, Caryn Libbey, Paul A Monach
PURPOSE: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with autoimmune diseases, but with limited evidence. This study tests the efficacy of LDN in reducing chronic pain in patients with osteoarthritis (OA) and inflammatory arthritis (IA), where existing approaches often fail to adequately control pain. METHODS: In this randomized, double-blind, placebo-controlled, crossover clinical trial, each patient received 4...
May 2023: Clinical Therapeutics
https://read.qxmd.com/read/37032996/segmental-darier-s-disease-a-case-report
#36
Elena Pastukhova, Lauren LaBerge
Segmental Darier's disease is an uncommon subtype of Darier's genodermatosis, resulting from a mutation in the ATPase type 2 during early embryogenesis. It typically presents as a persistent, pruritic papular eruption following the lines of Blaschko. Histopathology of Darier's disease demonstrates acantholysis, dyskeratosis, and corps ronds. First-line treatment includes topical retinoids, calcineurin inhibitors, and synthetic vitamin D analogues. Severe disease may require systemic therapy with oral retinoids, immunomodulators, magnesium, and low-dose naltrexone...
2023: SAGE Open Medical Case Reports
https://read.qxmd.com/read/37021443/low-dose-naltrexone-in-the-treatment-of-fibromyalgia-a-systematic-review-and-narrative-synthesis
#37
JOURNAL ARTICLE
Nicholas Aitcheson, Zhen Lin, Kristin Tynan
METHOD: A systematic literature search was conducted using the key words 'naltrexone', 'fibromyalgia', 'fibrositis', 'chronic pain' and 'neurogenic inflammation'. RESULTS: Manual exclusion led to the identification of 21 papers, with only five prospective controlled trials of low sample size. DISCUSSION: Low-dose naltrexone may be an effective and safe pharmacotherapy for patients with fibromyalgia. Current evidence lacks power and multisite reproduction...
April 2023: Australian Journal of General Practice
https://read.qxmd.com/read/37000135/compounding-for-the-treatment-of-covid-19-and-long-covid-part-2-manifestations-of-infection-nomenclature-transmission-and-treatment
#38
JOURNAL ARTICLE
Mike Riepl
Described by some authors as a "black swan event . . . likened to the economic scene of World War Two," the effects of coronavirus-disease-2019 (COVID-19) and attempted techniques for its prevention and treatment have presented medical, economic, social, and (often) politicized challenges on a global scale. Caused by the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 is, in many patients, associated with severe morbidity and mortality during the first few weeks after infection...
2023: International Journal of Pharmaceutical Compounding
https://read.qxmd.com/read/36974308/the-safety-and-efficacy-of-low-dose-naltrexone-in-patients-with-fibromyalgia-a-systematic-review
#39
REVIEW
Juan Yang, Kyung-Min Shin, Alex Do, Dennis M Bierle, Abd Moain Abu Dabrh, Ziying Yin, Brent A Bauer, Arya B Mohabbat
Fibromyalgia (FM) is a chronic pain sensitivity syndrome characterized by diffuse musculoskeletal pain and many other systemic manifestations. Low-dose naltrexone (LDN) has been increasingly used as an off-label treatment option in FM. However, current evidence on the safety and efficacy of LDN in patients with FM is not well known. To systematically assess the current evidence on the safety and efficacy of LDN use in the treatment of FM. A comprehensive bibliographic search was conducted on EBM Reviews - Cochrane Central Register of Controlled Trials, EBM Reviews - Cochrane Database of Systematic, Embase, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions and Scopus databases in September 2022...
2023: Journal of Pain Research
https://read.qxmd.com/read/36938272/diagnosis-and-management-of-a-hypersensitivity-reaction-to-titanium-containing-surgical-clips-a-case-report
#40
Darren N Ramcharan, Kayla L Alaimo, Frederick Tiesenga
Although titanium allergies are not commonly diagnosed, they can present with a variety of conditions years after the implantation of titanium-containing medical devices. Furthermore, there are few options to effectively manage the long-term outcomes of these conditions. We present the case of a 41-year-old female who experienced neck swelling, pain, and difficulty swallowing 16 years after a right thyroid lobectomy for benign follicular adenoma, requiring the implantation of titanium-containing surgical clips in her neck...
February 2023: Curēus
keyword
keyword
118814
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.